Published: Fri, April 21, 2017
Hi-Tech | By Ellis Neal

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Under Analyst Spotlight

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Under Analyst Spotlight

Currently, Agios Pharmaceuticals, Inc. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company's stock valued at $121,000 after buying an additional 216 shares during the period.

Brant Point Investment Management Llc increased Vca Inc (WOOF) stake by 2.44% reported in 2016Q4 SEC filing. Agios Pharmaceuticals, Inc. (AGIO) is a part of Healthcare sector and belongs to Biotechnology industry. The company has market cap of $2.16 billion. Agios Pharmaceuticals Inc (NASDAQ:AGIO) distance from 20 day simple moving average is -8.62% whereas its distance from 50 day simple moving average is -2.46% along with 4.36% distance from 200 day simple moving average.

9 number of analysts have estimated the sales of the company for the quarter ending May 3, 2017- May 8, 2017, analysts estimated mean sale target of 8.79 million while high and low sale targets are estimated at 15.72 million and 0 million respectively.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, February 16th. The analysts estimated EPS for the higher end at -1.08 and lower end at -1.97 while the year ago reported earnings per share was -1.21. The firm had revenue of $22.65 million for the quarter, compared to analysts' expectations of $10.89 million. (NASDAQ:AGIO) plummeted -3.22% to $48.74. The firm's revenue for the quarter was up 264.5% on a year-over-year basis.

EPS growth for this year is -61.30% and EPS growth for next year is expected to reach at 18.60%.

The share price of the company (NASDAQ:AGIO) was up +3.15% during the last trading session, with a high of 56.37 and the volume of Agios Pharmaceuticals, Inc. shares traded was 329507.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & global copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/04/20/agios-pharmaceuticals-inc-agio-ceo-sells-175860-00-in-stock-updated.html.

Several institutional investors have recently modified their holdings of the stock. TIAA CREF Investment Management LLC boosted its stake in Agios Pharmaceuticals by 4.5% in the third quarter. (AGIO). These ratios are important while doing valuation of the company or the shares of the company. First Mercantile Trust Co. purchased a new stake in Agios Pharmaceuticals during the third quarter valued at approximately $137,000. Moreover, Cubist Systematic Strategies Limited Liability Company has 0% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO). As per Monday, November 9, the company rating was maintained by Roth Capital.

University of MI professor and noted insider trading researcher, Nejat Seyhun, discovered that when insiders bought shares of their own companies, the stocks outperformed the total market by 8.9% over the following year while when they sold shares, the stock underperformed 5.4% over the same period. On Friday, April 1 the stock rating was initiated by CL King with "Buy".

Investors may be interested in viewing the Gross Margin score on shares of Agios Pharmaceuticals, Inc.

1/17/2017-CIBC Upgrade from a "Market Perform " rating to a " Outperform" rating.

Among 7 analysts covering VCA Antech (NASDAQ:WOOF), 3 have Buy rating, 0 Sell and 4 Hold.

Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) opened at 48.74 on Thursday. Finally, Canaccord Genuity set a $90.00 target price on shares of Agios Pharmaceuticals and gave the stock a "buy" rating in a research note on Thursday, February 16th.

In other Agios Pharmaceuticals news, insider Scott Biller sold 6,438 shares of the company's stock in a transaction dated Monday, March 20th. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its products include IDH1 AND IDH2, PKR, II D-2 hydroxyglutaric aciduria, AG-221 and AG-120.

Like this: